Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brain network pathophysiology in dystonia.

Dystonia (Lausanne, Switzerland)·2026

Same author

Parkinson's disease: Individual placebo responses are predicted by baseline expression of a striato-limbic network.

Research square·2026

Same author

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026

Same author

Non-invasive identification of brain signatures of acute liver injury.

Theranostics·2026

Same author

The Surgical Mindset: A Systematic Review of Personality Influences on Career Choice in Medicine.

Journal of surgical education·2026

Same author

Brain connectivity fingerprinting as a predictive biomarker of art therapy outcomes in Parkinson's disease.

Research square·2026

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease.

M Felice Ghilardi¹, Andrew S Feigin, Fortunato Battaglia

¹Department of Physiology & Pharmacology, CUNY Medical School at City College, City University of New York, 138th Street & Convent Avenue, New York, NY 10031, USA. liceg@sci.ccny.cuny.edu

Parkinsonism & Related Disorders

|October 24, 2006

Summary

Levodopa (L-Dopa) did not improve explicit sequence learning in Parkinson's disease (PD) patients, despite enhancing motor function. This suggests L-Dopa's cognitive benefits for PD may be limited, particularly in sequence learning tasks.

More Related Videos

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Jul 19, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

Neuroscience
Cognitive Science
Neurology

Background:

Explicit sequence learning, involving frontal lobe activation, is impaired in early Parkinson's disease (PD).
Previous research on Levodopa (L-Dopa) effects on cognitive symptoms in PD has produced conflicting findings.
The acute impact of L-Dopa on explicit sequence learning in PD remains unclear.

Purpose of the Study:

To investigate whether L-Dopa acutely enhances explicit sequence learning in individuals with Parkinson's disease.
To compare the effects of L-Dopa on both motor and visual sequence learning tasks.

Main Methods:

Six healthy subjects and seven PD patients were tested off-drug and during L-Dopa infusion.
Two sequence learning tasks were used: SEQ (motor-based) and VSEQ (visual-based).
Simple motor tasks assessed general motor performance and movement speed.

Main Results:

L-Dopa significantly improved motor scores and movement speed in participants.
No significant beneficial effect of L-Dopa was observed on either the SEQ or VSEQ tasks.
The drug did not enhance explicit sequence learning in PD patients.

Conclusions:

Acute L-Dopa administration does not improve explicit sequence learning in Parkinson's disease.
While L-Dopa benefits motor function in PD, its cognitive effects on specific learning tasks like sequence learning appear limited.
Further research is needed to understand L-Dopa's complex role in PD-related cognitive impairments.